# Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

> **NCT05768035** · PHASE1,PHASE2 · RECRUITING · sponsor: **Smart Immune SAS** · enrollment: 40 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **BIOLOGICAL:** Allogeneic T cell progenitors, cultured ex-vivo

## Key facts

- **NCT ID:** NCT05768035
- **Lead sponsor:** Smart Immune SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-06
- **Primary completion:** 2025-07
- **Final completion:** 2026-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768035, "Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05768035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*